[go: up one dir, main page]

MA35867B1 - Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh) - Google Patents

Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh)

Info

Publication number
MA35867B1
MA35867B1 MA37214A MA37214A MA35867B1 MA 35867 B1 MA35867 B1 MA 35867B1 MA 37214 A MA37214 A MA 37214A MA 37214 A MA37214 A MA 37214A MA 35867 B1 MA35867 B1 MA 35867B1
Authority
MA
Morocco
Prior art keywords
gnrh
receptor antagonists
diseases
spiroindoline derivatives
releasing
Prior art date
Application number
MA37214A
Other languages
English (en)
Inventor
Olaf Panknin
Stefan BÄURLE
Sven Ring
Wolfgang Schwede
Wilhelm Bone
Katrin Nowak-Reppel
Eckhard Bender
Reinhard Nubbemeyer
Mark Jean Gnoth
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35867(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35867B1 publication Critical patent/MA35867B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des dérivés de la spiroindoline, le procédé pour leur préparation et des compositions pharmaceutiques de ceux-ci, leur utilisation pour le traitement et/ou la prophylaxie de maladies, et leur utilisation pour la fabrication de médicaments pour le traitement et/ou la prophylaxie de maladies, notamment de maladies liées aux hormones sexuelles à la fois chez l'homme et la femme, en particulier celles choisies dans le groupe de l'endométriose, les fibromes utérins, la maladie des ovaires polykystiques, l'hirsutisme, la puberté précoce, les néoplasies gonadiques dues aux stéroïdes telles que les cancers de la prostate, du sein et des ovaires, les adénomes hypophysaires gonadotropes, l'apnée du sommeil, le syndrome du côlon irritable, le syndrome prémenstruel, l'hypertrophie prostatique bénigne, la contraception et l'infertilité (par exemple thérapie reproductive assistée telle que la fécondation in vitro). La présente invention concerne en particulier des dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh).
MA37214A 2012-01-16 2014-07-15 Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh) MA35867B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12151291 2012-01-16
PCT/EP2013/050676 WO2013107743A1 (fr) 2012-01-16 2013-01-15 Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh)

Publications (1)

Publication Number Publication Date
MA35867B1 true MA35867B1 (fr) 2014-12-01

Family

ID=47559493

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37214A MA35867B1 (fr) 2012-01-16 2014-07-15 Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh)

Country Status (25)

Country Link
US (1) US20140357655A1 (fr)
EP (1) EP2804867A1 (fr)
JP (1) JP2015503607A (fr)
KR (1) KR20140112075A (fr)
CN (1) CN104169287A (fr)
AP (1) AP2014007738A0 (fr)
AU (1) AU2013211091A1 (fr)
BR (1) BR112014017483A8 (fr)
CA (1) CA2860986A1 (fr)
CL (1) CL2014001871A1 (fr)
CO (1) CO7010832A2 (fr)
CR (1) CR20140343A (fr)
CU (1) CU20140088A7 (fr)
DO (1) DOP2014000167A (fr)
EA (1) EA201491344A1 (fr)
GT (1) GT201400153A (fr)
HK (1) HK1199878A1 (fr)
IL (1) IL233485A0 (fr)
MA (1) MA35867B1 (fr)
MX (1) MX2014008630A (fr)
PE (1) PE20141699A1 (fr)
PH (1) PH12014501616A1 (fr)
SG (1) SG11201403749VA (fr)
TN (1) TN2014000306A1 (fr)
WO (1) WO2013107743A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095785A1 (es) * 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
WO2015007606A1 (fr) * 2013-07-15 2015-01-22 Bayer Pharma Aktiengesellschaft Dérivés de spiroindoline et leurs compositions pharmaceutiques
WO2015082374A1 (fr) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Dérivés spiro indoline-thiopyrane-imine-oxydes utilisés comme antagonistes du récepteur de l'hormone de libération des gonadotrophines et compositions pharmaceutiques associées
EP2881391A1 (fr) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Dérivés de carbocycle spiroindoline et leurs compositions pharmaceutiques
WO2015091315A1 (fr) * 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Dérivés de spiro[indoline-3,4'-pipéridine] utilisés comme antagonistes du récepteur gnrh
EP3339846B1 (fr) * 2016-12-22 2020-12-09 Malvern Panalytical B.V. Procédé de mesure des propriétés d'une empilement de couches minces
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN107840851A (zh) * 2017-12-21 2018-03-27 扬州大学 吲哚螺吡咯嗪化合物及其合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds

Also Published As

Publication number Publication date
BR112014017483A2 (pt) 2017-06-13
DOP2014000167A (es) 2014-08-31
AP2014007738A0 (en) 2014-07-31
PE20141699A1 (es) 2014-11-29
CO7010832A2 (es) 2014-07-31
HK1199878A1 (en) 2015-07-24
CU20140088A7 (es) 2014-12-26
EP2804867A1 (fr) 2014-11-26
GT201400153A (es) 2015-05-22
US20140357655A1 (en) 2014-12-04
CL2014001871A1 (es) 2014-11-03
CR20140343A (es) 2014-09-08
EA201491344A1 (ru) 2015-04-30
AU2013211091A1 (en) 2014-08-07
MX2014008630A (es) 2014-08-29
BR112014017483A8 (pt) 2017-07-04
WO2013107743A1 (fr) 2013-07-25
IL233485A0 (en) 2014-08-31
TN2014000306A1 (en) 2015-12-21
CA2860986A1 (fr) 2013-07-25
KR20140112075A (ko) 2014-09-22
CN104169287A (zh) 2014-11-26
SG11201403749VA (en) 2014-07-30
JP2015503607A (ja) 2015-02-02
PH12014501616A1 (en) 2014-10-13

Similar Documents

Publication Publication Date Title
MA35867B1 (fr) Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh)
Griesinger et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction
HRP20191049T1 (hr) (11beta, 17beta)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentalfuorometil)estra-4,9-dien-3-on za uporabu za liječenje bolesti
JPH04506797A (ja) 性ステロイド活性の抑制における使用のためのアンドロゲン誘導体
JP4716726B2 (ja) 新しいエトノゲストレルエステル
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
MXPA03001320A (es) Agentes no peptidicos de la gnrh, composiciones farmaceuticas y procedimientos para su uso.
WO2007084211A3 (fr) Utilisation de ligands du gpr54 pour le traitement de troubles de la reproduction, de troubles proliferatifs et pour la contraception
KR20190009318A (ko) [8-(페닐설포닐)-3,8-디아자비사이클로[3.2.1]옥트-3-일](1h-1,2,3-트리아졸-4-일)메타논
MA38463B1 (fr) Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines
MX2022010439A (es) Antagonistas covalentes selectivos del receptor de androgenos (sarcas) y metodos de uso de los mismos.
KR20070035059A (ko) 17β-하이드록시스테로이드 데히드로게나제 1형의저해제로서의 신규한 2-치환된Ｄ-호모-에스트라-1,3,5(10)-트리엔
MA32477B1 (fr) Derives estratrienes comprenant des bioisosteres heterocycliques pour le cycle a phenolique
MA38465A1 (fr) Forme posologique de l'antagoniste du récepteur de la progestérone
BR9911564A (pt) Composto, processo para produzir um composto, composição farmacêutica, processo para antagonizar o hormÈnio de liberação de gonadotropina em um mamìfero, e, uso de um composto
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
CN116096371A8 (zh) 含有饱和含氧杂环基的嘧啶二酮类化合物及其用途
AR096905A1 (es) Derivados de espiroindolina y composiciones farmacéuticas de los mismos
TW201408306A (zh) 預防或治療雄性激素仲介之疾病的黃體激素受體調節劑或其代謝物
CN1898258B (zh) 具有混合的雄激素和结合孕激素特性的类固醇
Hantseva et al. Modern pharmacotherapy for menopause
Minorics Ontogeny and functions of the estrogen receptor subtypes in the pregnant rat uterus; the influence of stereoisomerism on ligand-receptor interactions
TN2011000022A1 (en) Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a - ring
James et al. Proceedings of the Fourth International Congress on Hormonal Steroids: Mexico City, September 1974
HUP0303219A2 (hu) Kinolin-, izokinolin- és ftalazinszármazékok mint gonadotropinfelszabadító hormon antagonisták és eljárás az előállításukra